NCT00026182

Rituximab and Interleukin-12 in Treating Patients With B-Cell Non-Hodgkin's Lymphoma

Randomized Phase II Study Of Interleukin-12 In Combination With Rituximab In Patients With Non-Hodgkin's Lymphoma

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 99 (actual)
• Sponsor: National Cancer Institute (NCI) · NIH
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Monoclonal antibodies, such as rituximab, can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Interleukin-12 may kill cancer cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to kill cancer cells. Combining rituximab with interleukin-12 may kill more cancer cells. This randomized phase II trial is comparing how well giving rituximab together with two different schedules of interleukin-12 works in treating patients with B-cell non-Hodgkin lymphoma.

Detailed description

OBJECTIVES: I. Compare the objective response in patients with B-cell non-Hodgkin's lymphoma treated with rituximab and 2 different schedules of interleukin-12\*. II. Compare the toxic effects of these regimens in these patients. III. Determine the objective response rate in patients with mantle cell lymphoma treated with these regimens. IV. Determine the overall and progression-free survival of patients treated with these regimens. V, Compare the quality of life of patients treated with these regimens. NOTE: \*Interleukin-12 will no longer be available after 6/30/05. OUTLINE: This is a randomized, multicenter study. Patients are stratified according to histology (mantle cell lymphoma vs other \[closed to accrual as of 3/10/04\]) and International Prognostic Factor Index (low and low-intermediate risk \[closed to accrual as of 3/10/04\] vs high-intermediate and high risk). Patients are randomized to 1 of 2 treatment arms. ARM I: Patients receive rituximab IV on days 1, 8, 15, and 22. Patients receive interleukin-12\* subcutaneously (SC) twice weekly beginning on day 2 and continuing until disease progression. ARM II (closed to accrual as of 11/14/03): Patients receive rituximab as in arm I. Patients are evaluated at week 12. Patients with stable or progressive disease receive interleukin-12\* SC twice weekly until disease progression or for 24 weeks. Patients with a complete or partial response after rituximab are monitored until disease progression and then begin interleukin-12 SC twice weekly until further disease progression. NOTE: \*Interleukin-12 will no longer be available after 06/30/05. Patients proceed to follow-up as outlined below. Quality of life is assessed at baseline and at 3 and 6 months. Patients are followed every 3 months for 1 year and then every 6 months for up to 4 years. PROJECTED ACCRUAL: A total of 90 patients (45 per treatment arm \[arm II closed to accrual as of 11/14/03\]) will be accrued for this study within 3 years.

Conditions

• Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
• Nodal Marginal Zone B-cell Lymphoma
• Recurrent Grade 1 Follicular Lymphoma
• Recurrent Grade 2 Follicular Lymphoma
• Recurrent Mantle Cell Lymphoma
• Recurrent Small Lymphocytic Lymphoma
• Splenic Marginal Zone Lymphoma

Interventions

Type	Name	Description
BIOLOGICAL	rituximab	Given IV
BIOLOGICAL	recombinant interleukin-12	Given SC
OTHER	laboratory biomarker analysis	Correlative studies
OTHER	questionnaire administration	Ancillary studies
PROCEDURE	quality-of-life assessment	Ancillary studies

Timeline

• Start date: 2001-10-01
• Primary completion: 2005-02-01
• First posted: 2003-01-27
• Last updated: 2013-08-26

Locations

1 site across 1 country: United States